Its underlying biology 'too complicated' for further investment, Atlas-seeded Raze signs off
Raze Therapeutics, the Cambridge startup that launched in 2014 with $24 million in support, is calling it quits.
The company was looking to advance a new class of cancer therapeutics that target key metabolic pathways, but it appears the science wasn’t quite ready for prime time.
Seeded in part by Atlas Venture, the company was focused on cancer anabolic metabolism, specifically mitochondrial one-carbon energetics. The space has emerged recently as a major driver of cancer proliferation, survival, and biomass accumulation. But apparently the tech was too tough to continue.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.